Tokyo, Oct 26, 2010 (JCN) - Asahi Kasei Pharma recently filed an application for approval to manufacture and sell MN-10-T (teriparatide acetate) as an osteoporosis drug in Japan.
Asahi Kasei's MN-10-T (generic name Teriparatide acetate, tentative product name Teribone) is aimed at osteoporosis with high risk of fracture (tentative).
Teriparatide acetate is a human parathyroid hormone preparation that facilitates bone formation. It has been verified that weekly subcutaneous injections of teriparatide acetate effectively inhibit new vertebral fracture. The efficacy in inhibiting fracture is obtained by increasing bone strength with both improved bone quality and increased bone density.
Asahi Kasei Pharma believes that, with its efficacy in inhibiting fracture, this drug will make a significant contribution to the treatment of osteoporosis, which is being suffered by more than 10 million in Japan alone.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Asahi Kasei Pharma Applies for Approval of Famvir for Additional Indication
(Feb 7, 2012)
|
|
|
Asahi Kasei Pharma Launches Flivas in South Korea
(Jan 13, 2012)
|
|
|
Asahi Kasei Pharma Launches Osteoporosis Drug in Japan
(Dec 6, 2011)
|
|
|
Artisan Pharma Now Wholly Owned Subsidiary of Asahi Kasei
(Nov 9, 2011)
|
|
|
Asahi Kasei to Build New Pharmaceutical Research Complex
(Nov 4, 2011)
|
|
|
Asahi Kasei Licenses Zosano Pharma Microprojection Technology for Teribone Hormone
(Oct 17, 2011)
|
|
|
Asahi Kasei Pharma Licenses XIAFLEX from Auxilium Pharmaceuticals
(Mar 23, 2011)
|
|
|
Asahi Kasei Targets Osteoporosis in Japan
(Oct 26, 2010)
|
|
|
Asahi Kasei Pharma Licenses Bisphosphonate Zoledronic Acid for Japan
(June 15, 2010)
|
|
|
Asahi Kasei Licenses Anti-glaucoma Drug to Altheos
(Apr 9, 2010)
|
|
|
|
|
|
|
Fujifilm Initiates Phase I Clinical Trial in Japan for Anticancer Agent FF-10501 (June 7, 2013)
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
More Drugs & OTC news...
|
|
|
|
|
|
Fujifilm Initiates Phase I Clinical Trial in Japan for Anticancer Agent FF-10501 (June 7, 2013)
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
More Medical news...
|
|
